Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Brexpiprazole

FDA-approved product (tablet, oral), marketed as Brexpiprazole, Rexulti.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Brexpiprazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Major depressive disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Brexpiprazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Brexpiprazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Brexpiprazole for Extended-Release Injection in Subjects With Schizophrenia

    NCT07742280 · start 2026-08

    Registered record
    Registry ID
    NCT07742280
    Conditions
    Schizophrenia
    Interventions
    Brexpiprazole for ER injection, 45 mg; Brexpiprazole for ER injection, 100 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-08
    Completion
    2027-12
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionBrexpiprazole for ER injection, 45 mg; Brexpiprazole for ER injection, 100 mg
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • Single-case Intervention Study for Visual Screening Assessment for Proof of Concept and Prediction of Clinical Response to Brexiprazole as Adjunctive Treatment in Adults With Major Depressive Disorder.

    NCT07723079 · start 2026-04-01

    Registered record
    Registry ID
    NCT07723079
    Conditions
    Depression - Major Depressive Disorder
    Interventions
    Eyetracking (Tobii Pro Fusion 250 hz)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2026-04-01
    Completion
    2026-08-01
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression - Major Depressive Disorder
    InterventionEyetracking (Tobii Pro Fusion 250 hz)
    PhaseNot applicable
    Registry statusActive not recruiting

  • REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)

    NCT06875986 · start 2025-04-17

    Registered record
    Registry ID
    NCT06875986
    Conditions
    Alzheimer Disease
    Interventions
    Brexpiprazole (Rexulti)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-04-17
    Completion
    2028-09-23
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionBrexpiprazole (Rexulti)
    PhaseNot recorded
    Registry statusRecruiting

  • The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.

    NCT06674694 · start 2024-04-10

    Registered record
    Registry ID
    NCT06674694
    Conditions
    Schizophrenia Disorders
    Interventions
    Brexpiprazole long-acting injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-04-10
    Completion
    2026-10-30
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia Disorders
    InterventionBrexpiprazole long-acting injection
    PhasePhase 1
    Registry statusRecruiting

  • Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

    NCT05017311 · start 2023-01-20

    Registered record
    Registry ID
    NCT05017311
    Conditions
    Major Depressive Disorder
    Interventions
    Escitalopram; Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-01-20
    Completion
    2029-04-30
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionEscitalopram; Brexpiprazole
    PhasePhase 4
    Registry statusRecruiting

  • A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline

    NCT05189977 · start 2022-09-07

    Registered record
    Registry ID
    NCT05189977
    Conditions
    Post-traumatic Stress Disorder (PTSD)
    Interventions
    Propranolol; Prazosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2022-09-07
    Completion
    2023-08-03
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-traumatic Stress Disorder (PTSD)
    InterventionPropranolol; Prazosin
    PhasePhase 1
    Registry statusTerminated

  • Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety

    NCT05504486 · start 2022-08-29

    Registered record
    Registry ID
    NCT05504486
    Conditions
    Major Depressive Disorder (MDD)
    Interventions
    Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2022-08-29
    Completion
    2023-04-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder (MDD)
    InterventionBrexpiprazole
    PhasePhase 4
    Registry statusWithdrawn

  • Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia

    NCT05325645 · start 2022-07-21

    Registered record
    Registry ID
    NCT05325645
    Conditions
    Acute Schizophrenia
    Interventions
    OPC-34712FUM/ Brexpiprazole fumarate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-07-21
    Completion
    2027-10
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Schizophrenia
    InterventionOPC-34712FUM/ Brexpiprazole fumarate; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia

    NCT05326347 · start 2022-05-31

    Registered record
    Registry ID
    NCT05326347
    Conditions
    Schizophrenia
    Interventions
    OPC-34712FUM/ Brexpiprazole fumarate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-05-31
    Completion
    2025-09-30
    Enrolment
    247

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionOPC-34712FUM/ Brexpiprazole fumarate
    PhasePhase 3
    Registry statusCompleted

  • Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia

    NCT05169268 · start 2022-02-01

    Registered record
    Registry ID
    NCT05169268
    Conditions
    Schizophrenia and Related Disorders; Anxiety Depression
    Interventions
    ARIPiprazole Injection [Abilify]; Brexpiprazole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-02-01
    Completion
    2026-01-31
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia and Related Disorders; Anxiety Depression
    InterventionARIPiprazole Injection [Abilify]; Brexpiprazole
    PhaseNot recorded
    Registry statusCompleted

  • Brexpiprazole Treatment for Bipolar I Depression

    NCT04569448 · start 2021-05-10

    Registered record
    Registry ID
    NCT04569448
    Conditions
    Bipolar Depression
    Interventions
    Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2021-05-10
    Completion
    2030-12
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Depression
    InterventionBrexpiprazole
    PhasePhase 3
    Registry statusRecruiting

  • Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

    NCT04830215 · start 2021-04-01

    Registered record
    Registry ID
    NCT04830215
    Conditions
    Major Depressive Disorder
    Interventions
    Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-04-01
    Completion
    2022-05-27
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionBrexpiprazole
    PhasePhase 4
    Registry statusCompleted

  • Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study

    NCT04162522 · start 2019-12-23

    Registered record
    Registry ID
    NCT04162522
    Conditions
    Major Depressive Disorder
    Interventions
    Escitalopram; Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-12-23
    Completion
    2022-12-31
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionEscitalopram; Brexpiprazole
    PhasePhase 3
    Registry statusCompleted

  • Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder

    NCT04174365 · start 2019-10-30

    Registered record
    Registry ID
    NCT04174365
    Conditions
    Irritability Associated With Autism Spectrum Disorder (ASD)
    Interventions
    Brexpiprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-10-30
    Completion
    2022-09-09
    Enrolment
    119

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritability Associated With Autism Spectrum Disorder (ASD)
    InterventionBrexpiprazole; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder

    NCT04100096 · start 2019-10-17

    Registered record
    Registry ID
    NCT04100096
    Conditions
    Borderline Personality Disorder
    Interventions
    Brexpiprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-10-17
    Completion
    2021-06-27
    Enrolment
    332

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBorderline Personality Disorder
    InterventionBrexpiprazole; Placebo
    PhasePhase 2
    Registry statusCompleted